Table 4

All-cause and neutropenia-related utilization by cycle
Total (N = 12,056) Filgrastim (N = 373) Pegfilgrastim (N = 11,683)
All-cause Hospitalizations n (%)* 620 (5.1) 38 (10.2) 582 (5.0)
Mean ± SD 0.06 ± 0.26 0.14 ± 0.46 0.05 ± 0.25
Ambulatory visits n (%)* 12,051 (100) 373 (100) 11,678 (100)
Mean ± SD 5.5 ± 3.7 9.5 ± 5.9 5.4 ± 3.5
Emergency room visits n (%)* 943 (7.8) 27 (7.2) 916 (7.8)
Mean ± SD 0.11 ± 0.46 0.09 ± 0.32 0.11 ± 0.46
Neutropenia- related Hospitalizations n (%)* 73 (0.61) 5 (1.34) 68 (0.58)
Mean ± SD 0.01 ± 0.08 0.02 ± 0.17 0.01 ± 0.08
Ambulatory visits n (%)* 3,422 (28.4) 148 (39.7) 3,274 (28.0)
Mean ± SD 0.42 ± 0.93 2.1 ± 3.3 0.36 ± 0.68
Emergency room visits n (%)* 32 (0.27) 1 (0.27) 31 (0.27)
Mean ± SD 0.00 ± 0.05 0.00 ± 0.05 0.00 ± 0.05

* Number of cycles with the event and percentage of those cycles among all cycles.

Mean and standard deviation of the number of events per cycle.

Naeim et al.

Naeim et al. BMC Cancer 2013 13:11   doi:10.1186/1471-2407-13-11

Open Data